Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 1/20 | 0.54 |
| ▸ | HTR1A | P08908 | 2/20 | 0.51 |
| ▸ | DRD2 | P14416 | 2/20 | 0.51 |
| ▸ | DRD4 | P21917 | 2/20 | 0.51 |
| ▸ | HTR2A | P28223 | 2/20 | 0.51 |
| ▸ | HTR2C | P28335 | 2/20 | 0.51 |
| ▸ | DRD3 | P35462 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.50 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.48 |
| ▸ | MGLL | Q99685 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | FABP3 | P05413 | 1/20 | 0.47 |
| ▸ | FABP4 | P15090 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | EGFR | P00533 | 1/20 | 0.46 |
| ▸ | RAF1 | P04049 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6514775 | 0.98 | KEAP1 (0.53) | NCF1HTR1ADRD2DRD4HTR2A | |
| Methylamine SCHEMBL6478870 | 0.96 | NCF1 (0.56) | NCF1HTR1ADRD2DRD4HTR2A | |
| Nitrogen SCHEMBL4600854 | 0.96 | NCF1 (0.51) | NCF1HTR1ADRD2DRD4HTR2A | |
| Ammonia Solution, Strong SCHEMBL7896018 | 0.96 | KEAP1 (0.52) | NCF1HTR1ADRD2DRD4HTR2A | |
| Hydrochloric Acid SCHEMBL29156848 | 0.96 | KEAP1 (0.52) | NCF1HTR1ADRD2DRD4HTR2A | |
| Hydrochloric Acid SCHEMBL28740234 | 0.92 | NCF1 (0.56) | NCF1HTR1ADRD2DRD4HTR2A | |
| SCHEMBL10424519 | 0.91 | HTR1A (0.59) | NCF1HTR1ADRD2DRD4HTR2A | |
| SCHEMBL21593838 | 0.86 | NCF1 (0.50) | NCF1HTR1ADRD2DRD4HTR2A | |
| SCHEMBL9263328 | 0.84 | HTR1A (0.50) | NCF1HTR1ADRD2DRD4HTR2A | |
| SCHEMBL2094689 | 0.84 | NCF1 (0.53) | NCF1HTR1ADRD2DRD4HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105579456-A | NOVEL NEUROKININ 1 RECEPTOR ANTAGONIST COMPOUNDS II | LEO PHARMA AS | 2016-05-11 | — | — | CN | claimed |
| EP-3558955-B1 | BENZISOTHIAZOLE, ISOTHIAZOLO[3,4-B]PYRIDINE, QUINAZOLINE, PHTHALAZINE, PYRIDO[2,3-D]PYRIDAZINE AND PYRIDO[2,3-D]PYRIMIDINE DERIVATIVES AS KRAS G12C INHIBITORS FOR TREATING LUNG, PANCREATIC OR COLORECTAL CANCER | AMGEN INC (US) | 2021-08-11 | — | — | EP | disclosed |
| EP-3788042-A1 | BCL-2 INHIBITORS | BeiGene, Ltd. (KY) | 2021-03-10 | — | — | EP | disclosed |
| US-20200399283-A1 | BRUTON'S TYROSINE KINASE INHIBITORS | VIRACTA THERAPEUTICS, INC. | 2020-12-24 | — | — | US | disclosed |
| US-10519146-B2 | KRAS G12C inhibitors and methods of using the same | AMGEN INC. (US) | 2019-12-31 | — | — | US | disclosed |
| US-10035768-B2 | C5aR antagonists | CHEMOCENTRYX, INC. (US) | 2018-07-31 | — | — | US | disclosed |
| WO-2018119183-A2 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. (US) | 2018-06-28 | — | — | WO | disclosed |
| US-20170190669-A1 | PYRAZOLE COMPOUNDS AND METHODS OF MAKING AND USING SAME | H. LUNDBECK A/S (DK) | 2017-07-06 | — | — | US | disclosed |
| US-20170174699-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | SHY Therapeutics LLC | 2017-06-22 | — | — | US | disclosed |
| CN-105579456-A | NOVEL NEUROKININ 1 RECEPTOR ANTAGONIST COMPOUNDS II | LEO PHARMA AS | 2016-05-11 | — | — | CN | disclosed |
| WO-2013091773-A1 | TETRAAZA-CYCLOPENTA[A]INDENYL AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS | MERCK PATENT GMBH (DE) | 2013-06-27 | — | — | WO | disclosed |
| EP-2305651-A1 | 2,3,6-trisubstituted-4-pyrimidone derivatives | Mitsubishi Tanabe Pharma Corporation (JP) | 2011-04-06 | — | — | EP | disclosed |
| EP-1751113-B1 | UREA ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS | BRISTOL MYERS SQUIBB CO (US) | 2010-03-10 | — | — | EP | disclosed |
| US-7173004-B2 | Macrocyclic isoquinoline peptide inhibitors of hepatitis C virus | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-02-06 | — | — | US | disclosed |
| EP-0809647-A1 | CHIRAL ORGANOMETALLIC COMPOUNDS | ZENECA LIMITED (GB) | 1997-12-03 | — | — | EP | disclosed |
| WO-1996025420-A1 | CHIRAL ORGANOMETALLIC COMPOUNDS | ZENECA LIMITED (GB) | 1996-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170190669-A1 | PYRAZOLE COMPOUNDS AND METHODS OF MAKING AND USING SAME | ABHD6, FAAH, FAAH2 | NCF1 3417/4885HTR1A 2993/4885DRD2 1469/4885 |
| US-10035768-B2 | C5aR antagonists | C5AR1, C5AR2, C3AR1 | NCF1 516/4885HTR1A 249/4885DRD2 1201/4885 |
| US-10519146-B2 | KRAS G12C inhibitors and methods of using the same | KRAS, NRAS, HRAS | NCF1 1500/4885HTR1A 4801/4885DRD2 4765/4885 |
| US-20200399283-A1 | BRUTON'S TYROSINE KINASE INHIBITORS | BTK, ABL1, SYK | NCF1 896/4885HTR1A 4686/4885DRD2 4760/4885 |
| US-20170174699-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | MAPK6, MAP3K6, MAPK4 | NCF1 298/4885HTR1A 4582/4885DRD2 4852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.